Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Dimension Therapeutics (NASDAQ:DMTX) Stock Price
News stories about Dimension Therapeutics (NASDAQ:DMTX) have trended somewhat positive this week, according to Accern. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dimension Therapeutics earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.7202071107478 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Dimension Therapeutics, Inc. (DMTX) Posts Quarterly Earnings Results, Hits Expectations (americanbankingnews.com)
- Zacks: Analysts Anticipate Dimension Therapeutics, Inc. (NASDAQ:DMTX) Will Announce Earnings of -$0.49 Per Share (americanbankingnews.com)
- Dimension Therapeutics, Inc. (NASDAQ:DMTX) Files An 8-K Results of Operations and Financial Condition (4-traders.com)
- Dimension Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update (finance.yahoo.com)
- Dimension Therapeutics reports 2Q loss (finance.yahoo.com)
A number of analysts have recently issued reports on the company. Chardan Capital restated a “hold” rating on shares of Dimension Therapeutics in a research report on Monday. Cantor Fitzgerald set a $3.00 price objective on Dimension Therapeutics and gave the company a “hold” rating in a research report on Saturday, June 10th. Canaccord Genuity lowered their price objective on Dimension Therapeutics from $20.00 to $12.00 and set a “buy” rating on the stock in a research report on Wednesday, June 28th. Zacks Investment Research cut Dimension Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, April 21st. Finally, Citigroup Inc. cut Dimension Therapeutics from a “buy” rating to a “neutral” rating and set a $1.50 price objective on the stock. in a research report on Friday, May 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $5.88.
Shares of Dimension Therapeutics (NASDAQ:DMTX) opened at 1.25 on Tuesday. The firm’s market cap is $31.30 million. Dimension Therapeutics has a 52 week low of $1.05 and a 52 week high of $9.98. The company has a 50-day moving average price of $1.35 and a 200 day moving average price of $1.55.
Dimension Therapeutics (NASDAQ:DMTX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.49) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.49). Dimension Therapeutics had a negative return on equity of 98.72% and a negative net margin of 358.21%. The firm had revenue of $4.37 million for the quarter. Analysts expect that Dimension Therapeutics will post ($2.17) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Dimension Therapeutics (NASDAQ:DMTX) Stock Price” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-dimension-therapeutics-nasdaqdmtx-stock-price/1488410.html.
About Dimension Therapeutics
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.